[Polivizumab against respiratory syncytial virus?].
Brunvand
L
L
Barnesenteret, Ullevål sykehus, Oslo. leif.brunvand@ulleval.no
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D016527:Drug Costs; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D015337:Multicenter Studies as Topic; D009664:Norway; D000069455:Palivizumab; D016032:Randomized Controlled Trials as Topic; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control*; D012141:Respiratory Tract Infections / Q000276:immunology / Q000517:prevention & control / Q000821:virology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab